BofA lowered the firm’s price target on Bausch + Lomb (BLCO) to $17 from $18 and keeps an Underperform rating on the shares. 2025 guidance, particularly EBITDA, likely disappointed investors even though B+L signaled lower expectations in early January, notes the analyst. The firm continues to believe the stock upside is limited until investors get more visibility into Bausch + Lomb’s separation from Bausch Health (BHC), the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLCO:
- Bausch + Lomb Reports Growth Amidst Revenue Challenges
- Bausch + Lomb price target lowered to $17 from $18 at JPMorgan
- Bausch + Lomb price target lowered to $17 from $18 at Stifel
- Bausch + Lomb Reports Robust 2024 Financial Performance and Strategic Growth
- Bausch + Lomb sees FY25 revenue $4.95B-$5.05B, consensus $5.02B